Mutational inactivation of the RB-related gene RBL2/ p130 has been reported as a common and important prognostic factor in human lung cancer. To examine the role of the RB-related gene family in lung cancer we analysed the protein expression of the RB gene in cell lines obtained from 83 patients with small cell lung cancer (SCLC) and 114 patients with non-SCLC that included 21 novel lung tumor samples. While we detected ®ve new SCLC with mutant RB expression (RB inactivation in 75/83; 90.4%), we did not detect any RB mutations in the new non-SCLC cell lines (RB inactivation in 13/114 non-SCLC and mesothelioma; 11.4%). In addition, we detected expression of a fulllength RBL1/p107 and RBL2/p130 species in every sample tested (RBL1 or RBL2 inactivation in 0/69) and con®rmed that both RB-related gene products retain functional binding activity to the E1A viral oncoprotein. Since expression of SV40 Large T antigen (Tag) has been reported in a subset of human lung tumors where it may inactivate RBL1 and RBL2, we also examined mesothelioma and non-mesothelioma lung tumors for Tag expression. Although we detected a faint 85 kDa protein species using speci®c anti-Tag antibodies, this signal migrated slightly faster than Tag extracted from Cos7 cells and did not exhibit binding activity to the RB or RBL1 proteins. Finally, we subjected 11 lung cancer cell lines to nucleotide sequencing and did not detect mutations within the C-terminal RBL2 exons 19 ± 22 as recently reported. While the RB/p16 tumor suppressor pathway is targeted for mutations in 100% of lung cancers, mutational inactivation of the related RBL1 and RBL2 genes is a rare event. Oncogene (2000) 19, 4632 ± 4639.
Introduction
Cytogenetic and loss of heterozygosity (LOH) analyses of samples isolated from patients with lung tumors have suggested a complex, multi-hit mutational pattern for the development of lung cancer. For example, tumorspeci®c allelic deletions have been detected at 430 dierent loci located on 21 dierent chromosomal arms in lung cancer samples (Kohno and Yokota, 1999) . While multiple DNA alterations are consistent with epidemiological data that implicate a long latency period following airway carcinogen exposures, it is important to de®ne each of the critical gene products for the development of lung cancer in order to devise new strategies for prevention, early detection and treatment.
The ®rst cancer gene identi®ed as a target for mutational inactivation in the etiology of human lung cancer was the retinoblastoma gene (RB) at chromosomal band 13q14 (Harbour et al., 1988; Yokota et al., 1988) . This unexpected observation suggested that a tumor suppressor gene for a rare familial eye cancer could have important growth regulatory roles for non-retinal tissue types and also provided direct evidence for a genetic distinction between the two major classes of human lung cancer: small cell lung cancer (SCLC) and non-SCLC. Although SCLC and non-SCLC arise following exposures to similar tobacco products, approximately 90% of SCLC samples have inactivated both alleles of the RB gene while only a minority (10 ± 15%) of non-SCLC and 0% of pulmonary mesotheliomas target the RB gene for inactivation (Kratzke et al., 1995; Shimizu et al., 1994) . Why the neuroendocrine tumor SCLC is so tightly linked with RB gene inactivation, while other endocrine and non-endocrine lung tumors such as typical and atypical carcinoid tumors, mesotheliomas, adenocarcinomas, squamous cell carcinoma, and large cell undierentiated carcinomas of the lung are not commonly associated with RB inactivation is still unde®ned.
The RB gene is part of a larger gene family that includes two other related genes designated as RBrelated protein 1, RBL1/p107 (referred here by thè Human Gene Nomenclature Database' designation of RBL1) and RB-related protein 2, RBL2/p130/pRB2 (referred here by the symbol RBL2). Much less is known about the biology of the RBL1 and RBL2 genes since, in contrast to RB, these genes have not been frequently implicated in human cancers. In addition, while RB null mice are embryonic lethal with defects in the dierentiation pathways of neural, hepatic, and hematopoietic lineages, RBL1 null or RBL2 null mice are viable in selected mouse strains (Dyson, 1998; Lee et al., 1996; Mulligan and Jacks, 1998; Nevins, 1998; Le Couter et al., 1998) . All three proteins have conserved two non-contiguous regions that fold onto each other to generate a globular binding domain which reversibly interacts with general transcription factors or other elements that regulate DNA chromatin structure to repress or activate transcription (Brehm and Kouzarides, 1999) . Although these genes are structurally related and each has conserved the ability to suppress tumor cell growth in vitro (Vairo et al., 1995; Claudio et al., 1994; Starostik et al., 1996; Zhu et al., 1993) , our understanding of how they interrelate with each other is still unde®ned. Despite these limitations, several lines of research suggest that the simultaneous inactivation of all three RB gene members may be required to manifest the fully transformed phenotype of mammalian cells. For example, studies of simian virus 40 (SV40) transformation show that an N-terminal domain of SV40 T antigen (Tag) is essential for selectively inactivating RBL1 and RBL2 functions and for inducing a fully transformed phenotype, even in RB 7/7 cell lines (Christensen and Imperiale, 1995; Zalvide et al., 1998) . These ®ndings suggest that loss of RB function alone is not sucient for the transformed phenotype and a complex cooperation may exist between RBL1, RBL2 and/or RB to prevent tumorigenesis. In addition, since the oncoproteins from several dierent DNA tumor viruses encode the ability to precipitate RB, RBL1 and RBL2 through an RBlike`pocket' domain, the possible contribution of SV40 infection in the pathogenesis of certain human tumors has received considerable attention (Butel and Lednicky, 1999; Carbone et al., 1997) .
In particular, the RBL2 gene has been extensively studied in human lung cancer. A recent study detected a splicing mutation within the RBL2 gene that resulted in absent protein expression in 1/17 lung cancer cell lines (Helin et al., 1997) . In addition, several other reports have demonstrated absent or reduced expression of the RBL2 protein in approximately 25 ± 30% of all lung cancer samples using immunohistochemical assays (Baldi et al., 1996; . These studies also observed a direct correlation between absent RBL2 staining and a more aggressive histologic grading and clinical phenotype. Immunohistochemical staining, however, has several pitfalls as a diagnostic assay for mutational inactivation. In particular, it is often dicult to reconcile focal or reduced immunohistochemical staining patterns with the underlying molecular defect in these lung cancer tumor sections. In addition, recent studies have reported mutations within the carboxy-terminal exons of the RBL2 gene in three of 10 nasopharyngeal tumor specimens and 11/14 lung cancers (Claudio et al., 2000a,b) . To examine the question of whether mutational inactivation of the RBL1 and RBL2 genes plays a role in the development of lung cancer, we have subjected the RBL2 gene to mutational analyses and have studied the protein status for RB, RBL1, RBL2 and Tag in lung cancer samples of diering histologic subtypes.
Results
We had previously de®ned the protein status of the RB gene in a series of lung cancer cell lines representing SCLC, non-SCLC, and mesotheliomas (Kratzke et al., 1995; Otterson et al., 1994; Shimizu et al., 1994) . Since these studies were published, our laboratory has established 21 new lung cancer cell lines and we have characterized the status of the RB gene in these samples using protein immunoblot analyses. Five of the six new SCLC cell lines showed RB inactivation with four exhibiting a truncated and/or mutant, hypophosphorylated RB species, one showed absent RB protein, and one showed a wildtype RB protein pattern scored by the ability to undergo hyperphosphorylation in vivo (Figure 1a) . The high frequency of detecting a stable, mutant RB species in these new SCLC samples re¯ects the improved sensitivity of current enhanced chemiluminescence visualization systems which would have been reported as`absent' protein expression with the [ 125 I]-protein A detection systems used in the initial studies. In contrast, we did not detect any examples of RB mutations from the new set of non-SCLC cell lines (Figure 1b , lanes 1, 2 and 4 ± 7). We have now compiled this data with that of other publications to present the RB status and histologic subtypes in 83 SCLC and 114 non-SCLC samples (Tables 1 and 2 ).
To address the issue of mutations of the RBL1/p107 and RBL2/p130 genes in human lung cancer, we randomly selected 69 lung cancer cell lines, including 33 SCLC and 36 non-SCLC, and performed protein immunoblot analyses. We observed detectable steadystate levels of full-length RBL1 protein species in all samples tested including both SCLC and non-SCLC ( Figure 2a , Table 3 ). Therefore, in contrast to the RB product where absent or aberrant protein expression can be easily detected, this data demonstrates that the RBL1 gene is not a target for inactivation by acquired somatic mutations which would either truncate or destabilize the mRNA and/or protein.
Absent expression of the RBL2 gene has been reported in 1/17 SCLC tumor cell lines (Helin et al., 1997) and other studies have observed that: (i) 30% of non-SCLC show absent or altered RBL2 staining by immunohistochemistry (Baldi et al., 1996 ; and (ii) 3/10 nasopharyngeal tumors (30%) and 11/14 lung Figure 1 Protein immunoblot analysis of lung cancer cell lines using a monoclonal a-RB antibody. (a) Protein analysis of six new SCLC cell lines (lanes 1 ± 6) and the previously reported H209 SCLC cell line which shows a mutant, hypophosphorylated RB product (lane 7) (Kaye et al., 1990) . (b) Protein analysis of six new non-SCLC lines (lanes 1, 2 and 4 ± 7). The previously reported H2712 non-SCLC cell line is shown as a control for a mutant phosphorylated RB product. Size marker in kilodaltons (kDa) are depicted on the left tumors (78.5%) show multiple nucleotide insertions and missense mutations that predict altered protein expression (Claudio et al., 2000a) . Therefore, we were surprised to also detect steady-state expression of fulllength RBL2 in all lung cancer samples tested ( Figure  2b , Table 3) . None of the samples tested for either RBL1 nor RBL2 showed a hypophosphorylated pattern since we were careful not to harvest tumor cells that were growth arrested post-con¯uency. We noted instead two dierent RBL2 phosphorylation patterns in the lung cancer cell lines that corresponded to either (i) a mixed hypo-and hyperphosphorylation pattern (detected under high resolution as a series of closely spaced bands) or (ii) a predominantly hyperphosphorylated species (detected as a discrete band with a slightly slower mobility pattern). The observation of full-length RBL2 in all samples shows that mutational inactivation or epigenetic gene silencing of RBL2 is a rare event in lung cancer. Although the large majority of inactivating mutations within the RB tumor suppressor gene results in either an absent or truncated protein species (Lohmann, 1999) , inactivating missense mutations can, rarely, give rise to a mutant full-length species (Kaye et al., 1990; Kratzke et al., 1994) . These aberrant proteins, however, can be easily detected on SDS ± PAGE analysis by the appearance of a discrete hypophosphorylated signal which re¯ects loss of normal cyclin dependent kinase (cdk)-mediated hyperphosphorylation. More importantly, each of these mutant species have defective RB protein`pocket' binding activity as measured by the ability to precipitate a family of proteins which encodes a Leucine-X-Cysteine-X-Glutamic acid (LXCXE) peptide sequence (such as E1a) or non-LXCXE proteins (such as E2F) (Weinberg, 1995) . To con®rm that the full-length signal detected on immunoblot analysis retained wildtype`pocket' binding activity, we selected multiple lung cancer samples, including all the samples that showed a predominantly hypophosphorylated RBL1 or RBL2 pattern, and tested for binding to the E1a oncoprotein. We demonstrated that the GST-E1a fusion protein eciently precipitated both RBL1 and RBL2 from every lung cancer samples examined while the control GST leader protein showed no binding activity (Figure 3 ). This observation supports the conclusion that, in contrast to the RB protein product, mutational inactivation of RBL1 or RBL2 is a rare event in lung cancer.
The absence of mutations within the RBL1 and RBL2 genes in lung cancer, however, does not necessarily imply that these genes have not been inactivated in some lung tumors. For example, the presence of simian virus 40 (SV40) DNA sequences using polymerase chain reaction methodology have been detected in 60% of human ependymomas, choroid tumors, and mesotheliomas and in a smaller subset of bone tumors and non-mesothelioma lung tumors (Bergsagel et al., 1992; Butel and Lednicky, 1999; Carbone et al., 1994 Carbone et al., , 1996 . In addition, Tag has been shown to bind to RB, RBL1 and RBL2 Howard et al., 1998; Zalvide and DeCaprio, 1995) where it may inactivate potential tumor suppressor activity. To examine whether the lung cancer samples with wildtype RBL1 and RBL2 protein expressed detectable Tag, we performed immunoblot analysis and tested for immunoreactivity to SV40 large T using dierent commercially available antibodies. Using protein A linked-[ 125 I] as a detection system to estimate quantitatively the relative levels of Tag protein expression, we detected high steady-state levels of Tag in Cos7 cells and a faint signal in an RB 7/7 non-SCLC sample (H2009) and in several mesothelioma samples (Figure 4a ). To investigate this signal further, we analysed a higher concentration of protein extract from the lung cancer samples using a more sensitive, but less quantitative, enhanced chemiluminescence detection system. Although this band was Figure 2 Protein immunoblot analysis of lung cancer cell lines using a monoclonal a-RBL1/p107 antibody (a) or a monoclonal a-RBL2/p130 antibody (b) as described in Materials and methods
Oncogene RB-related genes in lung cancer S Modi et al again detected in the mesothelioma and H2009 samples using antibodies directed against either the N-terminus or the C-terminus of Tag, we observed that it migrated slightly faster than the major Tag signal from Cos7 ( Figure 4b ). To test whether this slightly faster migrating species exhibited protein binding properties similar to that for Tag, we subjected 50 ± 100 mg of protein lysates from Cos7 cells and 500 mg of protein lysates from mesothelioma and non-mesothelioma lung cancers, to immunoblot analysis following precipitation with GST-RBL1. We observed that wildtype GST-RB and wildtype GST-RBL1, but not the missense point mutant controls GST-RBm or GST-RBL1m, eciently precipitated the major Tag signal from Cos7 cells, while the faster migrating species observed in both Cos7 cells and the lung cancer samples showed no binding activity ( Figure 5 ). Although we do not know the molecular basis for this slightly faster migrating species, the lack of binding to RB or RBL1 in this assay suggests that it does not function to inactivate RBL1/RBL2 in lung tumors. Finally, we recently noted several studies which reported that 11/14 primary lung tumors (78.5%) and 3/10 nasopharyngeal tumors show inactivating genetic alterations clustered within exons 19 ± 22 of the RBL2 gene (Claudio et al., 2000a,b) . These alterations were unusual because multiple adjacent nucleotide insertions and/or heterozygous missense substitutions were present in the same tumor sample and the same nucleotide insertion and/or missense alteration was noted to recur Figure 3 Intact pocket binding activity for RBL1 and RBL2 in lung cancer samples. 50 mg of total cellular protein was directly subjected to immunoblot analysis (7, lanes 1, 4, 7) or 250 mg protein from H510 (lanes 1 ± 3), H689 (lanes 4 ± 6), and H2009 (lanes 7 ± 9) were precipitated by either GST alone or GST-E1a followed by immunoblot analysis with either a-RBL1/p107 (a) or a-RBL2/p130 (b) in dierent tumor samples. Since these ®ndings were inconsistent with our data showing steady-state expression of full-length RBL2/p130 in all lung cancer samples tested, we subjected the same C-terminal RBL2 exons to nucleotide sequencing using the same primers and methodology as recently described (Claudio et al., 2000a,b) . We detected a wildtype RBL2 sequence in exons 19, 20, and 22 from 11/11 lung cancer cell lines tested. Nucleotide analysis of exon 21 using the sense primer, however, resulted in the appearance of multiple, heterozygous missense alterations that were distributed equally among the exon and adjacent intron sequences and which recurred in each of the 11 samples (data not shown). This observation suggested a suboptimal analysis rather than mutational clustering. We con®rmed this hypothesis by obtaining exclusively wildtype sequence from these samples by (i) using the reverse primer for directly sequencing the PCR product, and (ii) by subcloning the exon 21 fragment into the PCR-2.1 plasmid (Topo-TA kit, Invitrogen) and sequencing multiple independent clones with a T7 primer. These observations support the conclusion that, in contrast to the RB gene, mutational inactivation of the RB-related gene members is a rare event in lung cancer.
Discussion
The RB, RBL1, and RBL2 genes encode nuclear phosphoproteins that are widely expressed and that retain the capacity to suppress cell growth in vitro by reversibly interacting with a discrete family of cellular binding partners. A working hypothesis to interrelate the functional activities of this gene family proposes that each RB-like member preferentially binds to dierent cellular factors at distinct stages of the eukaryotic cell cycle to regulate cell growth (Dyson, 1998; Lipinski and Jacks, 1999; Nevins, 1998) . For example, recent reports have observed preferential binding of RBL2 to the E2F4 and E2F5 factors during the G0 phase of the cell cycle, while RB binds most eciently to E2F1, 2, and 3 prior to the G1 to S transition (Cobrinik et al., 1993; Corbeil et al., 1995; Dyson et al., 1993; Lees et al., 1993; Smith et al., 1996; Vairo et al., 1995) . Similarly, other studies have shown dierential binding of RB-like members to cyclin A, E and D (Wang et al., 1994) , to the Raf1 signal transduction element (Wang et al., 1998) , and to the dierentiation-linked transcription factor HBP1 and Pax-5 (Eberhard and Busslinger, 1999; Yee et al., 1998) again suggesting that subtle dierences in the binding properties of the RB pocket domain can result in an increased diversity of cellular responses. However, while the RB gene is inactivated in 100% of retinoblastoma tumors and has served as the paradigm for the concept of a tumor suppressor gene, the role of the RBL1 and RBL2 genes in human cancer is still unde®ned. Recent studies had demonstrated absent or reduced expression of the RBL2 gene in 30% of primary cancer samples which directly correlated with an aggressive clinical phenotype (Baldi et al., 1996 . In addition, a recent study reported a clustering of inactivating genetic alterations in 78% of primary lung cancers examined (Claudio et al., 2000b) . In contrast, we observed full-length RBL1 and RBL2 protein expression in each of the 33 SCLC and 36 non-SCLC samples tested using protein immunoblot analyses and no evidence for genetic inactivation within RBL2 exons 19 ± 22 in 11/11 lung cancer cell lines. Since most of these tumor cell lines were generated from patients with advanced or metastatic disease, these ®ndings suggest that mutational inactivation of RBL1 and RBL2 is a rare event which is not associated with an aggressive lung cancer phenotype.
An alternate mechanism to inactivate RB-related gene products arises from the ability of the transforming oncoproteins from human papillomavirus (HPV), adenovirus and SV40 to bind and inactivate the function of the p53 and RB-related proteins (Chellappan et al., 1992; Weinberg, 1995) . These observations have also suggested the possibility that these viruses may participate in human tumorigenesis. For example, there is growing evidence implicating the presence of SV40 viral infection as an etiologic agent in the majority of mesothelioma tumors and in a smaller subset of other lung cancer samples (Bergsagel et al., 1992; Butel and Lednicky, 1999; Carbone et al., 1994 Carbone et al., , 1996 . Using human cervical cancer and HPV infection as a model, however, a tight inverse correlation has been demonstrated between the expression of the transforming viral oncoprotein E7 and the components of the RB/p16 tumor suppressor Figure 5 GST-RB and GST-RBL1/p107 do not precipitate the faster migrating band in non-SCLC and mesothelioma samples. (a) 50 mg protein (Cos7) or 500 g protein from two non-SCLC samples (H3026 and H3072) were precipitated with either wildtype or mutant GST-RB and GST-RBL1/p107 as depicted and the washed pellets were subjected to immunoblot analysis with a-Tag (Pab419). (b) Identical precipitations were performed with three mesothelioma samples (H290, H2052, and H2596) using wildtype and mutant GST-RBL1/p107 pathway. For example, mutational inactivation of the RB/p16 pathway is largely restricted to the subset of human cervical cancer samples that are not infected with HPV, while cervical cancer cells expressing HPV E7 commonly show wildtype RB and p16 protein expression (Kelley et al., 1995; Schener et al., 1991) . In addition, HPV-infected cervical cancer samples show a pattern of over-expression of the p16 product that also serves as an indirect marker for RB inactivation (Kelley et al., 1995) . Finally, in situ staining of cervical cancer cells within a single tumor sample shows a consistent correlation between loss of viral E7 expression and inactivation of the RB/p16 pathway despite heterogeneous expression of viral E7 (Nuovo et al., 1999) . These observations conform to a model where the RB/p16 pathway is inactivated in these tumors by targeting only one of the components. In contrast to cervical cancer, several studies have noted absent p16 protein expression in 100% of mesothelioma primary tumors and derived cell lines (Kratzke et al., 1995; Otterson et al., 1994) . This ®nding, therefore, seems to obviate the need for SV40 infection with Tag expression to target the RB tumor suppressor pathway. In addition, the frequent detection of homozygous deletion within the p16 locus of primary mesothelioma tumors suggests that p53 function may also be inactivated through loss of p19arf signaling, obviating the need for Tag to target the p53 gene (Cheng et al., 1994; Pomerantz et al., 1998; Zhang et al., 1998) . The lack of correlation between p16 functional status and RBL1/RBL2 expression suggests that either the p16 cdk inhibitor does not directly regulate RBL1 and RBL2 phosphorylation/function and a separate tumor-speci®c event is required to inactivate these genes or that RBL1 and RBL2 are not essential targets for inactivation in human lung cancer. We tested the ®rst hypothesis by examining several mesothelioma and non-mesothelioma lung cancer samples for expression of SV40 Tag. Although we detected a discrete signal at approximately 85 kDa in most lung cancer samples using commercially available anti-Tag reagents, this band was less intense when quantitated using an 125 I-protein A detection system and consistently migrated slightly faster than the major Tag signal from Cos7 cells. Most importantly, although we could eciently precipitate the control Tag species from Cos7 cells using a GST-RB or GST-RBL1/p107 fusion bait, we observed no detectable precipitation of the faster migrating signal from any of the mesothelioma or other lung cancers samples tested. Although the need to coordinate the inactivation of all three members of the RB-like gene family in human cancer is biologically plausible, our data suggests that the RBL1 and RBL2 genes are not common targets for mutation in lung cancer.
Materials and methods

Patients and cell lines
Tumor samples from patients with histologically con®rmed lung cancer were obtained as part of approved investigational research protocols. Cell lines were generated from biopsy samples and propagated in RPMI media supplemented with 10% fetal bovine serum and penicillin/gentamycin as previously described (Carney et al., 1985) .
Protein analyses
Sub-con¯uent cells were harvested to avoid characteristic dephosphorylation changes in RB-like gene members that are associated with growth arrest from contact inhibition. Total cellular protein was extracted from 5610 6 cells in 500 ml lysis buer (50 mM Tris-HCl pH 7.5, 250 mM NaCl, 5 mM EDTA, 0.1% nonidet P-40, 50 mM NaF and 1 mM phenylmethylsulfonyl¯uoride) and maintained at 48C throughout. The cell extracts were vortexed for 5 s and microfuged for 5 min followed by quick-freezing of the supernatant. Fifty mg of total protein was subjected to 8% SDS ± PAGE followed by electroblotting to nitrocellulose membranes. Puri®ed antihuman RB antibody (epitope amino acids 300 ± 380, cat 14001A, PharMingen, San Diego, CA, USA), RBL1/p107 antibody (SC-318, Santa Cruz, Santa Cruz, CA, USA), RBL2/p130 antibody (SC-317, Santa Cruz), SV40 Tag (SC-147, Pab 101, SC-148, Pab 108, Santa Cruz and DP01, Pab419, Oncogene Research Products, Cambridge, MA, USA) were used for immunoblotting. Visualization of the protein signal was performed using either: (i) a polyclonal rabbit anti-mouse immunoglobulin (PharMingen) followed by a 2 h incubation with 2.5610 6 c.p.m. of 125 I-labeled protein A and autoradiography or (ii) using autoradiography enhanced chemiluminescence as recommended by the manufacturer (ECL, Amersham). If a full-length, hypophosphorylated signal was detected by immunoblot analysis for either RB, RBL1 or RBL2, another sub-con¯uent mass culture of the same cell line was re-tested to exclude the possibility of contact inhibition. In addition, all lung cancer samples that exhibited a predominantly underphosphorylated signal for RB-like species were subsequently tested for functional RB protein`pocket' binding activity using a GST-E1a pull-down assay.
GST-fusion protein pull down analyses
Wildtype 12S E1a cDNA was subcloned into the pGex3x vector (Pharmacia) to generate a GST-E1A fusion plasmid. GST-RBL1/p107 cDNA contains the functional RB-likè pocket' binding domain (A, B, and C domains), but lacks the N-terminal region. GST-RBL1/p 107 m contains a missense cysteine to phenylalanine substitution at codon 713 that results in null`pocket' protein binding activity (Ewen et al., 1991) . Bacterial stocks containing the designated GST plasmids were expanded, harvested, and puri®ed for the GST-fusion protein as previously described (Kaelin et al., 1991) . 500 mg total cellular protein was incubated with puri®ed GST fusion protein (approximately 20 ml bacterial growth per lane) for 1 h in NETN buer (Kaelin et al., 1991) . The washed pellets were separated by SDS ± PAGE and subjected to immunoblotting with the designated antibodies.
Nucleotide sequencing of RBL2
Genomic DNA was harvested from 11 lung cancer cell lines and subjected to polymerase chain reactions (PCR) using paired oligonucleotide primers as recommended (Claudio et al., 2000a,b) . Direct nucleotide sequence of the PCR products was obtained by dideoxy chain termination methods using the sense and/or antisense primers for RBL2 exons 19 ± 22 (Claudio et al., 2000a,b) . The PCR fragment from exon 21 was also subcloned into the PCR-2.1 plasmid (Topo-TA kit, Invitrogen) and multiple independent clones were subjected to nucleotide sequencing using a T7 polymerase oligonucleotide primer.
